In the top 10 cancers with the highest PRKDC mutation frequency from the TCGA dataset, the TMB in samples with PRKDC mutations was significantly higher than in those without PRKDC mutations (median nonsynonymous mutations 1278 vs. 109, P < 0.0001 for stomach adenocarcinoma; 1450 vs. 99, P < 0.0001 for colorectal adenocarcinoma; 1529 vs. 45, P < 0.0001 for uterine corpus endometrioid carcinoma). This evidence concerns the gene PRKDC and cancer.